The last quarter of 2026 is unusually crowded for anyone responsible for pharmacovigilance, quality or regulatory compliance. A revised EU inspection guideline took effect in September, an FDA data standard changed on 1 October, and the largest rewrite of EU GMP computerised systems and documentation rules in fifteen years is expected to be finalised before the year ends. Each of these has its own owner inside most companies, and that is exactly the problem: the work overlaps, but the calendars do not.
This guide pulls the main items into one working calendar, explains what is already in force and what is still pending, and sets out what each team should be doing between now and the end of the year. If you are searching for pharmacovigilance compliance calendar 2026, Annex 11 revision timeline, GVP Module III Rev 2 compliance actions, or E2B(R3) readiness plan, this is written for you.
A Note on What Is Final and What Is Not
Before the calendar, it is worth being clear about status, because mixing up a final rule with a draft is one of the easiest ways to waste budget:
- GVP Module III Revision 2 is final and in force since 10 September 2026
- FDA’s E2B(R3) requirement for postmarketing ICSRs is final and in force since 1 October 2026
- EU GMP Annex 11 (computerised systems), Annex 22 (artificial intelligence) and Chapter 4 (documentation) are still drafts. The 2011 version of Annex 11 remains the one in force today
- The EMA GMP and GDP Inspectors Working Group lists Q4 2026 as its target for giving the European Commission a final text for Chapter 4, Annex 11 and Annex 22, a date that moved from an earlier Q1 2026 target in the previous work plan
- Final texts, once published, are typically followed by a transition period before they apply, with six to twelve months a common pattern, although the actual dates will be set in the final documents
Treat anything about application dates for the three GMP documents as a planning assumption, not a fact, until the final texts appear.
October 2026: Confirm the Cutovers and Check Your Vendors
October is the month for verifying that the two changes already in force are working.
For E2B(R3):
- Review the first weeks of FDA acknowledgements and rejections, and fix patterns at root cause
- Reconcile cases received, processed and submitted across the cutover, so you can prove no gaps in reporting
- Confirm that every partner and service provider has finished its own migration
- Update SOPs, the PSMF and training records, since FDA also now refers to its database as AEMS rather than FAERS
For GVP Module III Revision 2:
- Pull out every pharmacovigilance vendor contract and check whether it obliges the vendor, and its own subcontractors, to accept inspection
- Map the full subcontracting chain, including systems and data processors that hold safety data
- Record the inspection arrangements wherever tasks are subcontracted onwards
These two workstreams share a theme, which is that the paperwork must catch up with the technology and the outsourcing model.
November 2026: Test Readiness and Close Gaps
November is when mock exercises pay off, because there is still time to fix what they reveal.
- Run an unannounced mock inspection for pharmacovigilance, including at least one vendor, with a realistic request for the PSMF and sample ICSRs
- Review the risk factors that EU inspection planners consider, such as a change of QPPV, a change of safety database, new contracts, or a transfer of PSMF management, and document any change made this year
- Check that CAPA items from earlier audits are closed with evidence, with critical and major items prioritised
- For GMP sites, run a gap assessment against the draft Annex 11, Chapter 4 and Annex 22, focusing on identity and access management, audit trail control, supplier oversight and the treatment of electronic records
- Start a list of AI and machine learning tools used anywhere in GxP processes, with their intended use and level of human oversight
The draft Annex 11 is far more prescriptive than the 2011 text, which was only a few pages long, so a gap assessment now is cheaper than a remediation project later.
December 2026: Watch for Final Texts and Plan the Transition
December is likely to be the month in which regulators publish or hand over final documents, so the focus shifts from doing to monitoring and planning.
- Monitor the European Commission and EMA for final versions of Chapter 4, Annex 11 and Annex 22
- Once published, compare the final text with the draft you assessed, and update the gap analysis rather than starting again
- Confirm the application date and transition period, then build the remediation plan around them
- Plan inspector expectations: EMA’s work plan includes training for EU GMP inspectors on the revised Chapter 4, Annex 11 and Annex 22 across 2026 to 2028, which suggests inspectors will be applying the new texts with some confidence once they are in force
- Review your pharmacovigilance and quality budgets for 2027, including any regulatory fee changes announced by the MHRA
Other Items Worth a Place on the Calendar
Several other developments overlap with the three headline changes and are worth tracking:
- EU GMP revisions targeting the end of 2026 also include Chapter 1 on the pharmaceutical quality system, Annex 15 on qualification and validation with extension to active substances, ATMP GMP guidelines, an EU approach to ICH Q12 lifecycle management, and a GDP Q&A on verifying product authenticity
- FDA has continued to update its eCTD v4.0 packages and technical conformance documents through the summer of 2026, which matters for regulatory operations teams
- The MHRA’s new UK Clinical Trials Regulations came into effect on 28 April 2026, with updated guidance on serious breach notification that sponsors should have embedded by now
- EMA has opened a concept paper consultation on revising the biosimilar guideline, running to 31 October 2026, which is relevant for biosimilar developers
- The EMA has also published a concept paper proposing major changes to its pharmacogenomics guideline, including the role of pharmacogenomics in pharmacovigilance
Who Should Own What
A calendar only works if each item has a named owner and a review date. A simple split helps:
- Head of pharmacovigilance or QPPV: GVP Module III actions, vendor oversight, PSMF changes
- Safety database owner and IT quality: E2B(R3) cutover review and validation records
- Head of quality: Annex 11, Chapter 4 and Annex 22 gap assessment, data integrity programme
- Regulatory affairs: monitoring of final texts and communication to the board
- Finance and operations: budgeting for 2027 remediation and fees
Practical Steps for the Quarter
- Create one shared regulatory change register covering PV, GMP, GDP and regulatory operations
- Give every item an owner, a status (in force, draft or consultation) and a review date
- Run one cross-functional meeting a month, so that overlaps between workstreams are caught early
- Record every decision and its rationale, because inspectors ask why as well as what
- Keep a short list of assumptions, such as the expected transition period for Annex 11, and revisit each one as new information is published
Turning the Calendar Into an Action Plan
A calendar only has value when it becomes work that gets done and evidenced. Quality and Vigilance Ltd supports clients in turning overlapping regulatory changes into a single plan, alongside its core pharmacovigilance and regulatory affairs services covering the MHRA, EMA and FDA. The most useful help at this stage usually includes:
- Building a regulatory change register that covers pharmacovigilance, GMP and GDP in one place
- Carrying out gap assessments against GVP Module III Revision 2, E2B(R3) and the draft Annex 11, Chapter 4 and Annex 22
- Reviewing vendor contracts and outsourcing arrangements for inspection access and oversight
- Running mock inspections that test both pharmacovigilance and quality systems
- Preparing remediation plans and budgets that are ready to start the moment final texts are published
Get in touch with Quality and Vigilance Ltd today to turn your Q4 2026 regulatory calendar into a plan your team can deliver.